Thursday 16 October, 2025
Objectives: Combination therapies may dramatically improve the outcome for cancer patients, and it is expected that such Therapies will eventually…
Read morePoster: Drug/Disease Modelling - Oncology
in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics.
Thursday 16 October, 2025
Introduction: T-Cell Bispecifics (TCBs) are antibody constructs with binding specificities to both a tumor antigen and T cell receptor allowing…
Read moreA review of population PK and exposure-response models reported in FDA oncology submission documents
Thursday 16 October, 2025
Objectives: Population pharmacokinetic (popPK) and exposure-response (ER) modelling are the critical components of United States Food and Drug Administration (FDA)…
Read moreModel-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics
Thursday 16 October, 2025
Objectives: In 2011, Madlensky et al. [1] established an efficacy threshold for endoxifen, (ENDX), the active metabolite of tamoxifen (TAM)….
Read moreModel-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2
Thursday 16 October, 2025
Objectives: BI-1808 is a novel immunotherapy targeting tumor necrosis factor receptor 2 (TNFR2), which is abundantly expressed on tumor-resident regulatory…
Read moreOptimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue
Thursday 16 October, 2025
Objectives: Pancreatic adenocarcinoma is one of the most lethal human malignancies and a major health issue. FOLFIRINOX regimen is commonly…
Read moreIntegrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice
Thursday 16 October, 2025
Objectives: Erlotinib is a tyrosine kinase inhibitor that exerts its action intracellularly. Integrating a dynamic tumour growth inhibition model within…
Read morePopulation PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies
Thursday 16 October, 2025
Introduction: Overexpression of murine double minute 2 (MDM2), a key negative regulator of the tumour suppressor protein p53, has been…
Read morePopulation PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies
Thursday 16 October, 2025
Introduction: Overexpression of murine double minute 2 (MDM2), a key negative regulator of the tumour suppressor protein p53, has been…
Read moreModel-informed precision dosing of protein kinase inhibitors: benefits and limits. The example of imatinib.
Thursday 16 October, 2025
Objectives: In model-informed precision dosing (MIPD), therapeutic drug monitoring (TDM) concentration data are analyzed by means of a population pharmacokinetic…
Read more